Please login to the form below

Not currently logged in
Email:
Password:

Horizon Discovery appoints Eric Rhodes as chief technical officer

Former Sangamo Biosciences VP of business development to join personalised medicine specialists

Eric Rhodes - Horizon, chief technology officerEric Rhodes has been appointed chief technical officer at UK-based Horizon Discovery.

Rhodes joins the personalised medicine specialists from his role as business development director at life science and technology company Sigma-Aldrich Corp.

In his new position, Rhodes will use his experience of gene-targeting therapeutics to advise R&D and marketing for Horizon's rAAV-mediated genome editing technology, this enables genes in a human cell-line to be altered quickly and reliably, according to the company.

Prior to his position as Sigma-Aldrich, Rhodes was VP of business development at Sangamo Biosciences, a clinical stage biopharmaceutical company that focuses on DNA research, from 1998 until 2008.

In both roles he was responsible for the commercialisation of gene-editing technology, during which time he made licensing deals with more than 24 biotech and pharma companies.

Dr Darrin Disley, CEO of Horizon, said: “Eric has a proven track record of delivery in the biotech industry, backed by a broad knowledge of the gene-editing field, and so brings added perspective to our technology, IP and commercial strategies.

“I'm delighted to welcome him to Horizon, and look forward to seeing him make an impact within an innovative, dynamic and entrepreneurial environment.”

27th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics